197 related articles for article (PubMed ID: 8757150)
1. Calcium-channel blockade and incidence of cancer in aged populations.
Pahor M; Guralnik JM; Ferrucci L; Corti MC; Salive ME; Cerhan JR; Wallace RB; Havlik RJ
Lancet; 1996 Aug; 348(9026):493-7. PubMed ID: 8757150
[TBL] [Abstract][Full Text] [Related]
2. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the nurses' health study.
Michels KB; Rosner BA; Walker AM; Stampfer MJ; Manson JE; Colditz GA; Hennekens CH; Willett WC
Cancer; 1998 Nov; 83(9):2003-7. PubMed ID: 9806660
[TBL] [Abstract][Full Text] [Related]
3. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old.
Pahor M; Guralnik JM; Furberg CD; Carbonin P; Havlik R
Lancet; 1996 Apr; 347(9008):1061-5. PubMed ID: 8602055
[TBL] [Abstract][Full Text] [Related]
4. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux.
Vaughan TL; Farrow DC; Hansten PD; Chow WH; Gammon MD; Risch HA; Stanford JL; Schoenberg JB; Mayne ST; Rotterdam H; Dubrow R; Ahsan H; West AB; Blot WJ; Fraumeni JF
Cancer Epidemiol Biomarkers Prev; 1998 Sep; 7(9):749-56. PubMed ID: 9752982
[TBL] [Abstract][Full Text] [Related]
5. Do calcium channel blockers increase the risk of cancer?
Pahor M; Guralnik JM; Salive ME; Corti MC; Carbonin P; Havlik RJ
Am J Hypertens; 1996 Jul; 9(7):695-9. PubMed ID: 8806983
[TBL] [Abstract][Full Text] [Related]
6. Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study.
Beiderbeck-Noll AB; Sturkenboom MC; van der Linden PD; Herings RM; Hofman A; Coebergh JW; Leufkens HG; Stricker BH
Eur J Cancer; 2003 Jan; 39(1):98-105. PubMed ID: 12504665
[TBL] [Abstract][Full Text] [Related]
7. Using medication history to measure confounding by indication in assessing calcium channel blockers and other antihypertensive therapy.
Leader S; Mallick R; Roht L
J Hum Hypertens; 2001 Mar; 15(3):153-9. PubMed ID: 11317198
[TBL] [Abstract][Full Text] [Related]
8. Use of calcium channel blockers as antihypertensives in relation to mortality and cancer incidence: a population-based observational study.
Lindberg G; Lindblad U; Löw-Larsen B; Merlo J; Melander A; Råstam L
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):493-7. PubMed ID: 12426934
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study.
Ellis JS; Seymour RA; Steele JG; Robertson P; Butler TJ; Thomason JM
J Periodontol; 1999 Jan; 70(1):63-7. PubMed ID: 10052772
[TBL] [Abstract][Full Text] [Related]
10. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging.
Maxwell CJ; Hogan DB; Ebly EM
CMAJ; 1999 Sep; 161(5):501-6. PubMed ID: 10497605
[TBL] [Abstract][Full Text] [Related]
11. The safety of calcium-channel blockers.
Massie BM
Clin Cardiol; 1998 Dec; 21(12 Suppl 2):II12-7. PubMed ID: 9853194
[TBL] [Abstract][Full Text] [Related]
12. Calcium channel blockers and cancer.
Cohen HJ; Pieper CF; Hanlon JT; Wall WE; Burchett BM; Havlik RJ
Am J Med; 2000 Feb; 108(3):210-5. PubMed ID: 10723975
[TBL] [Abstract][Full Text] [Related]
13. Slow infusion of calcium channel blockers compared with intravenous adenosine in the emergency treatment of supraventricular tachycardia.
Lim SH; Anantharaman V; Teo WS; Chan YH
Resuscitation; 2009 May; 80(5):523-8. PubMed ID: 19261367
[TBL] [Abstract][Full Text] [Related]
14. Rapid large artery remodeling following the administration and withdrawal of calcium channel blockers in spontaneously hypertensive rats.
Vaja V; Ochodnicky P; Krenek P; Klimas J; Bajuszova Z; Kyselovic J
Eur J Pharmacol; 2009 Oct; 619(1-3):85-91. PubMed ID: 19683522
[TBL] [Abstract][Full Text] [Related]
15. Calcium-channel blockers and cancer.
Oliver S
Lancet; 1996 Oct; 348(9035):1165; author reply 1167. PubMed ID: 8888181
[No Abstract] [Full Text] [Related]
16. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.
Gress TW; Nieto FJ; Shahar E; Wofford MR; Brancati FL
N Engl J Med; 2000 Mar; 342(13):905-12. PubMed ID: 10738048
[TBL] [Abstract][Full Text] [Related]
17. Long-term use of calcium channel blocking drugs and breast cancer risk in a prospective cohort of US and Puerto Rican women.
Wilson LE; D'Aloisio AA; Sandler DP; Taylor JA
Breast Cancer Res; 2016 Jul; 18(1):61. PubMed ID: 27378129
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous adverse reactions associated with calcium channel blockers.
Stern R; Khalsa JH
Arch Intern Med; 1989 Apr; 149(4):829-32. PubMed ID: 2523214
[TBL] [Abstract][Full Text] [Related]
19. Identifying iatrogenic depression using confirmatory factor analysis of the Center for Epidemiologic Studies Depression Scale in patients prescribed a verapamil-sustained-release-led or atenolol-led hypertension treatment strategy.
Wilson DL; Ried LD
Res Social Adm Pharm; 2012; 8(4):309-20. PubMed ID: 22133650
[TBL] [Abstract][Full Text] [Related]
20. Use of calcium channel blockers in hypertension.
Conlin PR; Williams GH
Adv Intern Med; 1998; 43():533-62. PubMed ID: 9506192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
